EGFR and breast carcinoma: A recent paper by Savage et al.observed heterogeneous EGFR expression in breast cancer patient-derived xenografts (PDX) and showed that the sensitivity to EGFR inhibitors such as gefitinib is determined by the variation rather than the mean EGFR expression; PDX models bearing heterogeneous expression of EGFR were more sensitive towards gefitinib46.